PHILADELPHIA (PRWEB) July 21, 2021
InfraScan, a medical device firm specializing in traumatic brain injury diagnostic products, announces today their Defense Health Agency Small Business Innovation Research (SBIR) Sequential Phase II contract. In June, InfraScan announced its product development partnership with the United States Department of Defense (DoD) and The Defense Health Agency (DHA) to further expand the Infrascanner device technology.
Recognizing that it takes a long time to mature a technology, the SBIR/STTR Reauthorization Act of 2011 allows a Phase II awardee to receive one additional sequential Phase II award, to continue the work of an initial Phase II award. This additional sequential Phase II contract has the same guideline amounts and limits as the initial Phase II contract.
“This contract reinforces the commitment to identify innovative and cost-saving traumatic brain injury technology.” Said Baruch Ben Dor, PhD, president and CEO of InfraScan.
InfraScan has over 1,000 devices deployed in the US and internationally, including with some of the world's leading neurotrauma and trauma experts. InfraScan also licensed a variety of patents that apply to hemorrhagic and ischemic stroke detection and brain hemorrhage monitoring.
About InfraScan, Inc.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing and distributing portable brain scanner for head injury and stroke assessment based on near infrared (NIR) technologies. The company has received funding from the U.S. Army Medical Materiel Development Activity, U.S. Marine Corps, Office of Naval Research, BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, and from the Philadelphia Industrial Development Corporation. For more information visit http://www.infrascanner.com and follow us @infrascanner.
Vice President of Business Development